We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

6 hedge funds and large institutions have $194K invested in Windtree Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

20% more funds holding

Funds holding: 5 → 6 (+1)

0% more ownership

Funds ownership: 0% → 0.01% (+0%)

2% less capital invested

Capital invested by funds: $198K → $194K (-$3.6K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$37.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$37K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$9.18K
2
UBS Group
UBS Group
Switzerland
-$5.29K
3
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$190

WINT Hedge Fund Activity: Q4 2023 in Review

6 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q4 2023, worth a combined $194K — down 1.8% from $198K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new WINT positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $37.9K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $9.18K sold.

  • 6 institutional investors held Windtree Therapeutics (WINT) as of Q4 2023, up from 5 in Q3 2023.
  • Funds reported $194K of Windtree Therapeutics stock for Q4 2023, down 1.8% quarter-over-quarter.
  • 2 funds opened new Windtree Therapeutics positions in Q4 2023 and 1 closed out, a net change of +1 holder.
  • The largest Windtree Therapeutics buyer in Q4 2023 was Virtu Financial, an estimated $37.9K added.
  • The largest Windtree Therapeutics seller in Q4 2023 was Tower Research Capital (TRC), an estimated $9.18K sold.

Based on aggregated 13F filings for Q4 2023.